Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care

NCT ID: NCT03613155

Last Updated: 2019-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-04

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The emergency setting, frequently associated with pain and the feeling of loss of control, can cause anxiety in patients.

Reaction anxiety may be an appropriate response to an emergency; Nevertheless, attention must be paid to the evaluation and management of the latter especially as anxiety and pain are closely linked.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is a definite interest in the management of patients' pre-hospital anxiety. The literature reports a strong association between anxiety, post-traumatic stress and chronic pain. A study conducted at SAMU 31 also found that anxiety on arrival at the emergency department was a negative factor in the treatment of pain. Anxiety can reduce the pain threshold and promote hyperalgesia.

The management of patient anxiety in pre-hospital offers interesting results in terms of analgesia and satisfaction of users of care and should not be neglected.

MEOPA has recently been available in SMUR vehicles (emergency and resuscitation mobile service) at SAMU 31 (urgent medical assistance service); its availability can lead teams to change their practices. More and more emphasis is placed on the importance of positive communication and comfort for which MEOPA, with its conscious sedating effect, could be a facilitating factor.

The aim of our study is to evaluate the level of anxiety of patients treated by SMUR teams in Toulouse and receiving MEOPA following the usual indications for pain-induced pain or pain alleviation.

This is a pilot study, which focuses on the assessment of anxiety in patients treated in pre-hospital care by SMUR Toulouse and receiving MEOPA as part of their care. No data exists in the literature on this subject.

This descriptive study based on qualitative data collected by the FAS1 scale will provide us with the first data on this population. It does not change the usual management of the patient since only patients who must receive MEOPA following the usual indications for pain relief or pain-induced care will be included in the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Administration of MEOPA as part of the care

Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18
* Patient supported by a SMUR team from Toulouse
* Patient receiving MEOPA during pre-hospital care (in the usual indications for pain relief or pain-induced care)
* Patient having given his non-opposition to participate in the study

Exclusion Criteria

* Any patient with a contraindication to MEOPA:
* Patient requiring pure oxygen ventilation
* Intracranial hypertension
* Any alteration of the state of consciousness preventing the patient's cooperation
* Traumatic brain injury
* Pneumothorax
* Emphysema bubbles
* Gas embolism
* Diving accident
* Abdominal gas distension
* Patient who received an ophthalmic gas for ocular surgery less than three months old
* Known and unsubstituted vitamin B12 deficiency
* Patient under legal protection
* Refusal of the patient to participate in the study
* Barrier of the language or alteration of the communication
* Patient in vital distress
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Toulouse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vincent Bounes, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Toulouse

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A01687-48

Identifier Type: OTHER

Identifier Source: secondary_id

RC31/18/0222

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Trust Game and Placebo Response
NCT02578212 COMPLETED NA
Modulation of Painful Perception
NCT02528578 COMPLETED NA